MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5414/cn111986

Медицинская библиотека · Clinical nephrology · 2026

Rituximab improves the control of pediatric nephrotic syndrome and reduces healthcare utilization.

Zeid Ahmed, Phillips Melonie, Sethna Christine, Deepti Narla, Chishti Aftab S, Pizzo Helen, Stone Hillarey, Warejko Jillian, Greenbaum Larry, Smoyer William E, Mahan John D, Kallash Mahmoud

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Rituximab (RTX) is often used in children with nephrotic syndrome (NS), but there is lack of consensus on its dose among pediatric nephrologists. This study aimed to assess its efficacy in controlling NS and impact on healthcare utilization in children with NS.

MATERIALS AND

METHODS

This is a retrospective multicenter study of children with primary NS who were treated with RTX between 2013 and 2017. Summary statistics were used to describe the data. Variables were analyzed using Fisher's exact test or Mann-Whitney U test where indicated.

RESULTS

The study included 50 children from 6 centers. At 12 months, 71.5% of steroid-sensitive NS (SSNS) patients and 37.5% of steroid-resistant NS (SRNS) patients achieved sustained remission. The median time to relapse was 16 months for the SSNS group and 7 months for the SRNS group. The median time to relapse was 7 months when receiving 1 infusion vs. 17 months for those receiving 2 RTX infusions. The rate of hospital admissions per patient-year significantly decreased from 0.53 to 0.11 after RTX treatment, without an increase in infection-related admissions.

CONCLUSION

RTX is largely an effective treatment in children with SSNS leading to long remission periods and a substantial decrease in hospitalizations, with a low risk of serious infections.

Для цитирования: Zeid Ahmed, Phillips Melonie, Sethna Christine, Deepti Narla, Chishti Aftab S, Pizzo Helen, Stone Hillarey, Warejko Jillian, Greenbaum Larry, Smoyer William E, Mahan John D, Kallash Mahmoud. Rituximab improves the control of pediatric nephrotic syndrome and reduces healthcare utilization.. Clinical nephrology. 2026. DOI: 10.5414/cn111986.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.